TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
Phase 1
Completed
- Conditions
- Ovarian Neoplasms
- Registration Number
- NCT00051948
- Lead Sponsor
- Telik
- Brief Summary
This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
Santa Monica Hematology/Oncology Consultants
🇺🇸Santa Monica, California, United States
Midwest Cancer Research Group, Inc.
🇺🇸Skokie, Illinois, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
M.D. Anderson Cancer Center
🇺🇸Houston, Texas, United States
Santa Monica Hematology/Oncology Consultants🇺🇸Santa Monica, California, United States